+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evolving treatment paradigms for locally advanced and metastatic prostate cancer



Evolving treatment paradigms for locally advanced and metastatic prostate cancer



Expert Review of Anticancer Therapy 6(11): 1639-1651



While men with early stage prostate cancer typically enjoy long-term survival after definitive management, for those who present with locally advanced or metastatic disease, survival is compromised. Multimodality therapy can prolong survival in these patients, with state-of-the-art options including intensity-modulated radiation or brachytherapy in conjunction with androgen ablation, adjuvant androgen ablation and/or chemotherapy with radical retropubic prostatectomy. In addition, novel biological therapies are being explored to target the unique molecular changes in prostate cancer cells and their interactions with the microenvironment. With these advances the outlook will undoubtedly improve, even for patients presenting with advanced disease. Careful application of these emerging therapies to a select group of prostate cancer patients most likely to obtain benefit from them is the challenge for urologists, medical oncologists and radiation oncologists for the future.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049009117

Download citation: RISBibTeXText

PMID: 17134367

DOI: 10.1586/14737140.6.11.1639


Related references

Locally-advanced prostate cancer in the elderly: should we revisit our treatment paradigms?. Asian Journal of Andrology 17(5): 769-770, 2015

Current treatment of locally advanced and metastatic prostate cancer. Wiener Medizinische Wochenschrift 161(15-16): 377-381, 2012

Castration in the treatment of locally advanced or metastatic prostate cancer. La Revue du Praticien 63(4): 509-510, 2013

Evolving therapeutic paradigms for advanced prostate cancer. Oncology 25(6): 496-504, 508, 2011

Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer. Progres en Urologie 21 Suppl 3: S96-101, 2011

Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematology/Oncology Clinics of North America 15(3): 423-443, 2001

Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update. Progres en Urologie 19 Suppl 1: S15-S19, 2009

Evaluating the Safety of Up-front Docetaxel in the Treatment of Metastatic and Locally Advanced Prostate Cancer. Clinical Oncology 31(2): e22-e23, 2019

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. European Journal Of Cancer. 29a(8): 1088-1093, 1993

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms. Prostate Cancer 2013: 210686, 2013

Evolving therapeutic paradigms for advanced prostate cancer: what's needed to make optimal use of the new treatments. Oncology 25(6): 514-515, 2011

Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?. Archivio Italiano di Urologia, Andrologia 89(4): 282-286, 2018

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 33(5): 447-456, 1998

Unmet Supportive Care Needs of Men With Locally Advanced and Metastatic Prostate Cancer on Hormonal Treatment: A Mixed Methods Study. Cancer Nursing 40(6): 497-507, 2017

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer interim analysis of an ongoing poncap study. European Urology 18(SUPPL 3): 48-53, 1990